Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent Or Metastatic Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: August 13, 2009
Last updated: October 3, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)